A Novel Compound for Alcoholism Treatment

NCT02039349 | Completed Phase 1

• 2 other identifiers: 14004214-AA-0042
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

Background: \- Hormones are naturally occurring chemicals in your body. Ghrelin is a hormone that is mainly produced by the stomach and stimulates appetite. Some studies suggest it may stimulate alcohol craving and use. Drugs have been developed that block ghrelin. Researchers want to know if people can tolerate a particular drug that blocks ghrelin. It will be given at two dose levels, combined with alcohol. Objective: \- To determine if a drug that may decrease alcohol consumption when given along with alcohol is safe and tolerable. Eligibility:

• Healthy adults 21-65 years old who have 14 (women) to 21 (men) drinks a week.
• No one of childbearing potential can participate. Design:
• Participants will have 3 inpatient clinic visits; each will last 4 days.
• They will have physical exam and blood and urine tests.
• They will have breath tests for alcohol and smoking.
• They will answer health and mood questions.
• Researchers will measure their reaction to smelling alcohol and tasting a sweet drink.
• They will eat only the food provided by the clinic. They will keep a food diary 1 day before each stay.
• They will be randomly assigned to take the study drug or placebo 5 times each stay.
• On Day 3, they will drink alcohol after taking the drug. They will give many blood samples that day through a tube inserted in their skin.
• Smokers can take smoke breaks. Once, they will smoke a cigarette through a device.
• One week after the last stay, participants will have a follow-up visit to answer questions.

Conditions

Alcoholism; Alcohol-Related Disorders; Alcohol Dependence; Alcohol Drinking Related Problems; Alcohol Drinking

Keywords

Alcoholism; Ghrelin; Ghrelin Antagonism

Outcome Measures

Primary Outcomes (1)

• Side effects/adverse events and maximum tolerated dose of PF-05190457 alone and in combination with alcohol administration.

  3 days

Interventions

PF-05190457 DRUG

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females 21-65 years old (inclusive);
• Heavy drinking defined as on average at least 21 drinks per week for men or at least 14 drinks for women based on the timeline follow-back (TLFB) done at screening.
• Be in good health as confirmed by medical history, physical examination, ECG, blood/urine lab tests;
• Female subjects must be of non childbearing potential as defined by at least one of the following criteria:
• Females 45 65 years old, who are menopausal, defined as follows:
• Females who are between 45 55 years old: they will be considered menopausal if they satisfy all the following three requirements during screening: 1) they are in amenorrhea, defined as absence of menstruation for the previous 12 months; 2) they have a negative urine pregnancy test; and 3) they have a serum FSH level within the laboratory s reference range for postmenopausal females.
• Females who are between 56 65 years old: they will be considered menopausal if they are in amenorrhea, defined as absence of menstruation for the previous 12 months before screening.
• Females 21-65 years old, who have a documented hysterectomy and/or bilateral oophorectomy.
• All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy) will be considered to be of childbearing potential.
• Male subjects must use one of the following methods of contraception from the first dose of study medication and until 28 days after dosing:
• Abstinence.
• A condom AND one of the following:
• Vasectomy for more than 6 months.
• Female partner who meets one of the following conditions:
• Has had a tubal ligation, hysterectomy, or bilateral oophorectomy;

You may not qualify if:

• Interest in receiving treatment for heavy drinking.
• Current DSM-IV diagnosis (based on SCID) of substance dependence (other than alcohol and/or nicotine); a negative urine drug screen will also be required.
• DSM-IV Axis I criteria for a lifetime diagnosis of schizophrenia, bipolar disorder, or other psychoses;
• Active illness within the past 6 months of the screening visit that meet the DSM-IV criteria for a diagnosis of major depressive disorder or anxiety disorder; subjects with a history of attempted suicide will be excluded;
• Clinically significant medical abnormalities (e.g., unstable hypertension, clinically significant EKG abnormalities, Creatinine greater than or equal to 2 mg/dL, liver cirrhosis, AST or ALT \> 3x the upper normal limit, hemoglobin \<10.5 g/dl);
• Heart rate \>100 at screening on two separate measurements given potential of study medication to increase heart rate.
• BMI less than or equal to 18.5 or anorexia given potential of the study medication to reduce appetite.
• BMI greater than or equal to 35 kg/m\^2.
• Naltrexone, acamprosate, alcohol dehydrogenase inhibitors, topiramate, gabapentin, ondansetron, benzodiazepines, beta-blockers, H2-blockers, and alpha-1 blockers, baclofen, and barbiturates as well as hormone replacement therapy; medications and dietary/herbal supplements (like St. John's wort) that interact with Cytochrome P450 3A4. All of the medications in the previous sentence will not be allowed if they have been taken within 2 weeks of study medication administration.
• PF-05190457 is a substrate for P-glycoproteins (P-gp or encoded by ABCB1 gene) based on information from in vitro or animal models. Patients that are required to take the following inhibitors and inducers of P-gp are excluded unless the subject stops taking these agents for 2 weeks for P-gp inhibitors or 6 weeks for P-gp inducers before study medication administration.
• Inhibitors: Amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, cyclosporine, diltiazem, dronedarone, erythromycin, felodipine, itraconazole, ketoconazole, lopinavir and ritonavir, quercetin, quinidine, ranolazine, verapamil
• Inducers: Avasimibe, carbamazepine, phenytoin, rifampin, St John s wort, tipranavir/ritonavir \[From Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, table 12, from http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#substrates\]
• History of epilepsy or alcohol-related seizures;
• patients who have diabetes and/or are treated with any drug with glucose lowering properties such as sulfonylurea, insulin, metformin, thiazolidinediones (TZD), Dipeptidyl peptidase-4(DPP4) inhibitors, or Glucagon-like peptide-1(GLP-1)agonists (due to the glucose-lowering properties of PF-05190457 observed in healthy volunteers);
• History of alcohol-induced flushing reactions.

Sponsors & Collaborators

• National Institute on Alcohol Abuse and Alcoholism (NIAAA): lead
• National Center for Advancing Translational Sciences (NCATS): collaborator
• University of Rhode Island: collaborator

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (8)

• Leggio L, Schwandt ML, Oot EN, Dias AA, Ramchandani VA. Fasting-induced increase in plasma ghrelin is blunted by intravenous alcohol administration: a within-subject placebo-controlled study. Psychoneuroendocrinology. 2013 Dec;38(12):3085-91. doi: 10.1016/j.psyneuen.2013.09.005. Epub 2013 Sep 13.

  PMID: 24090583 BACKGROUND

• Leggio L, Ferrulli A, Cardone S, Nesci A, Miceli A, Malandrino N, Capristo E, Canestrelli B, Monteleone P, Kenna GA, Swift RM, Addolorato G. Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol. 2012 Mar;17(2):452-64. doi: 10.1111/j.1369-1600.2010.00308.x. Epub 2011 Mar 11.

  PMID: 21392177 BACKGROUND

• Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, Kenna GA. Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry. 2014 Nov 1;76(9):734-41. doi: 10.1016/j.biopsych.2014.03.019. Epub 2014 Mar 25.

  PMID: 24775991 BACKGROUND

• Leggio L. Role of the ghrelin system in alcoholism: Acting on the growth hormone secretagogue receptor to treat alcohol-related diseases. Drug News Perspect. 2010 Apr;23(3):157-66. doi: 10.1358/dnp.2010.23.3.1429490.

  PMID: 20440417 BACKGROUND

• Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM, Khot V, Kong J, Kosa RE, Lapham K, Loria PM, Londregan AT, McClure KF, Orr ST, Patel J, Rose C, Saenz J, Stock IA, Storer G, VanVolkenburg M, Vrieze D, Wang G, Xiao J, Zhang Y. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. ACS Med Chem Lett. 2014 Feb 24;5(5):474-9. doi: 10.1021/ml400473x. eCollection 2014 May 8.

  PMID: 24900864 BACKGROUND

• Cobbina E, Lee MR, Leggio L, Akhlaghi F. A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers. Clin Pharmacokinet. 2021 Apr;60(4):471-484. doi: 10.1007/s40262-020-00942-7. Epub 2020 Nov 5.

  PMID: 33155163 DERIVED

• Lee MR, Farokhnia M, Cobbina E, Saravanakumar A, Li X, Battista JT, Farinelli LA, Akhlaghi F, Leggio L. Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: Results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers. Neuropharmacology. 2020 Jun 15;170:107788. doi: 10.1016/j.neuropharm.2019.107788. Epub 2019 Sep 23.

  PMID: 31557492 DERIVED

• Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, Jackson VM. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. Br J Clin Pharmacol. 2017 Feb;83(2):326-338. doi: 10.1111/bcp.13127. Epub 2016 Oct 29.

  PMID: 27621150 DERIVED

MeSH Terms

Conditions

Alcoholism; Alcohol-Related Disorders; Alcohol Drinking

Interventions

PF-5190457

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Drinking Behavior; Behavior

Study Officials

• Lorenzo Leggio, M.D.

  National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2014
• First Posted: January 17, 2014
• Study Start: January 3, 2014
• Primary Completion: October 1, 2015
• Study Completion: December 24, 2017
• Last Updated: December 16, 2019

Record last verified: 2017-12-24

Locations

US (1)